Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3291-3300 Newer>

The Motley Fool November 20, 2006 Brian Gorman	Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
The Motley Fool November 20, 2006 Karl Thiel	Trimeris Begs for a Buyout The pharmaceutical's reorganization plan practically posts a "for sale" sign. So will Roche -- or someone else -- bite? Investors, take note.
Entrepreneur December 2006	Good Genes Dyadic International has developed enzymes for use in the production of jeans and paper. They are now using enzymes to develop a system for gene discovery and manufacturing that will result in new, affordable medicines.
The Motley Fool November 17, 2006 Brian Lawler	Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note.
The Motley Fool November 17, 2006 Brian Lawler	Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
American Family Physician November 15, 2006 Liz Smith	Newsletter AAFP adopts new physician workforce policy to counter family physicians shortage... Medicare and Medicaid services propose allowing use of part D data for research initiatives... etc.
Bio-IT World November 2006 John Russell	Pathway Pioneers Innovative uses for pathway tools and exciting results from early users are sprouting like mushrooms after a spring rain -- albeit following a few harsh winters. And the usually risk-averse pharmaceutical industry has led in adopting pathway tools.
Bio-IT World November 2006 Wendy Wolfson	Oracle OpenWorld 2006: Pharma Stuck on Semantic Web At the recent Oracle OpenWorld conference, pharma executives offered evidence that some, at least, are using the semantic web to work smarter and lower drug development costs.
Bio-IT World November 2006 Kevin Davies	Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology.
<Older 3291-3300 Newer> Return to current articles.